"Pen-Type Drug Injection Device and Optical Dose Value Decoding System with Additional Sensor to Distinguish between Dose Dialling and Dose Delivery Mode" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventor Draper, Paul Richard, filed on August 21, 2017, wa
By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventor SAMBELASHVILI, Aleksandre T., filed on July 31, 2017, was made available online on December 7, 2017, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application has not been assigned to
By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventors McLennan, Kevin P.; Hoenninger, III, John C., filed on May 10, 2017, was made available online on December 7, 2017, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application has not b
By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventor Liu, Jian-Hung, filed on December 15, 2016, was made available online on December 7, 2017, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application has not been assigned to a company
Conagra shares gained 1.21 percent to $38.60 in after-hours trading. Analysts expect Nike Inc to post quarterly earnings at $0.4 per share on revenue of $8.39 billion after the closing bell. Nike shares declined 1.01 percent to close at $63.59 on Wednesday. Allergan plc reported that the FDA has accepted NDA for Seysara for treatment of moderate to
Although there are still a few days left for the year to end, 2017 has turned out to be pretty good for the pharma and biotech sector where FDA approvals are concerned. Immuno-oncology was a key focus area in 2017, whether it was to do with scientific conferences, clinical trial collaborations, acquisitions or FDA approvals. The $11.9 billion acqui
Gainers AEterna Zentaris Inc. rose 69.1 percent to $3.39 in pre-market trading after the company reported the FDA approval of Macrilen for diagnosis of adult growth hormone deficiency. Net Element International Inc rose 50.6 percent to $29.20 in the pre-market trading session following Wednesday announcement of Blockchain business unit. NXT-ID Inc.
Washington DC- 60 Degrees Pharmaceuticals announced it has submitted a New Drug Application to the United States Food and Drug Administration for the use of Tafenoquine to prevent malaria in adults traveling to areas where malaria is prevalent. Malaria, a life-threatening disease caused by Plasmodium parasites that are transmitted to people through
Southwest Community Health Center provides health care for uninsured residents of Southwest Portland. Ever since Donald Trump was elected president and Republicans retained majorities in the Senate and House of Representatives, immigration reform and health care policy have dominated the national political agenda. And all of that, says Southwest...
Pune, India 12/21/2017 Global Auto-Injectors Market is expected to reach USD 2.4 billion by the end of the forecasted period and is expected to grow at a CAGR of~ 17.2%. Auto-injectors is defined as a medical device which is designed to deliver a single dose of a particular life-saving drug. Key Players for Global Auto-Injectors Market:- UNIL
New York Attorney General Eric T. Schneiderman issued the following news release:. Attorney General Eric T. Schneiderman today announced a $13.5 million agreement with Boehringer Ingelheim Pharmaceuticals, Inc., resolving alleged deceptive and misleading marketing regarding drug usage beyond what is indicated on the labeling of four of its prescrip
-Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today that the first patient in a Phase 1/ 2 clinical trial for ABO-101, a single treatment gene therapy for patients with Sanfilippo syndrome type B, has been dosed at Natio
Pune, India 12/21/2017 High-intensity focused ultrasound therapy is a novel, emerging, and therapeutic modality technology. The American Cancer Society estimated that about 161,360 new cases of prostate cancer have been registered in the US in year 2017. Global High-Intensity Focused Ultrasound Therapy Market- Competitive Analysis.
Accenture today announced a collaborative services agreement with Roche. Under the terms of this exclusive multi-year agreement, Accenture will provide digital data integration services to Roche's NAVIFY Tumor Board solution. The data integration capabilities Accenture provides will allow Roche to integrate patient data between hospitals and the...
Aerie Pharmaceuticals` Rhopressa has secured Food and Drug Administration approval for use as an alternative to beta blockers in glaucoma patients that fail to respond adequately to prostaglandin analogues. There are 60 million cases of glaucoma worldwide, and according to the World Health Organization, glaucoma is the second leading reason why peo
AEterna Zentaris Inc. moved skyward Thursday after the company reported the FDA approval of Macrilen for diagnosis of adult growth hormone deficiency. The Company estimates that approximately 60,000 tests for suspected AGHD are being conducted each year across the United States, Canada and Europe. In the absence of an FDA- approved diagnostic te
Montana Attorney General Tim Fox issued the following news release:. Attorney General Tim Fox announced today a $13.5 million settlement with Boehringer Ingelheim Pharmaceuticals, Inc.. I'm pleased Montana joined with all other states and the District of Columbia to send a clear message that deceptive business practices by pharmaceutical companies
New Jersey Attorney General Christopher S. Porrino issued the following news release:. Attorney General Christopher S. Porrino announced today that New Jersey has entered into a $13.5 million, multi-state settlement that resolves allegations that Boehringer Ingelheim Pharmaceuticals, Inc. unlawfully promoted certain prescription drugs for off-label
Florida Attorney General Pam Bondi issued the following news release:. Attorney General Pam Bondi and 50 other attorneys general reached a $13.5 million settlement with Boehringer Ingelheim Pharmaceuticals, Inc. regarding alleged off-label marketing and deceptive and misleading representations to promote four prescription drugs.
North Carolina Attorney General Josh Stein issued the following news release:. Attorney General Josh Stein announced today that North Carolina and 49 other states and the District of Columbia have reached a $13.5 million settlement with Boehringer Ingelheim Pharmaceuticals, Inc. regarding its alleged off-label marketing and deceptive and misleading
DUBLIN, IRELAND- Allergan plc, a global biopharmaceutical company, today announced that VISTABEL has received a Positive Opinion from the Agence Nationale de Securite du Medicament et des Produits de Sante for the temporary improvement in the appearance of moderate to severe forehead lines in adults when the severity of the facial lines has an impo
WASHINGTON- Allergan plc, and Paratek Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted New Drug Application to review Seysara for moderate to severe acne vulgaris in patients 9 years of age and older. Allergan has U.S. rights to the development and commercialization of Seysara. Allergan owns the U.S. rights to
Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced it has completed dosing of its HepTcell Phase 1 study in chronic hepatitis B. All doses were well tolerated, there were no hepatic flares, and no discontinuations. Additionally, the preliminary data showed evidence of dose dependent increases in cellular immune response
-via OTC PR Wire Amarantus Bioscience Holdings, Inc., a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary MANF Therapeutics, Inc. was issued a patent by the Japan Patent Office entitled
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age related macular degeneration and fibrotic diseases, and Ambrx, Inc., today announced that they have entered into a licensing agreement for the development and commercialization o